Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
21.81
+0.41 (1.92%)
At close: Dec 5, 2025, 4:00 PM EST
22.24
+0.43 (1.97%)
After-hours: Dec 5, 2025, 6:16 PM EST
Enliven Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Cash & Equivalents | 101.73 | 124.12 | 100.14 | 75.54 | 110.02 | 130.37 |
| Short-Term Investments | 375.83 | 189.32 | 153.01 | - | - | - |
| Cash & Short-Term Investments | 477.57 | 313.44 | 253.15 | 75.54 | 110.02 | 130.37 |
| Cash Growth | 63.64% | 23.82% | 235.14% | -31.35% | -15.60% | - |
| Prepaid Expenses | 5.12 | 4.63 | 2.95 | 2.22 | 0.65 | 0.06 |
| Restricted Cash | - | 0.05 | 0.05 | - | - | 0.05 |
| Other Current Assets | - | - | 10 | - | - | 0.1 |
| Total Current Assets | 482.68 | 318.13 | 266.15 | 77.75 | 110.67 | 130.59 |
| Property, Plant & Equipment | 0.87 | 0.46 | 1.06 | 1.52 | 0.95 | 0.42 |
| Long-Term Deferred Charges | 0.22 | - | 0.56 | 3.98 | 1.65 | - |
| Other Long-Term Assets | 7.1 | 7.18 | 4.09 | 0.05 | 0.05 | - |
| Accounts Payable | 1.43 | 1.34 | 0.53 | 3.44 | 2.52 | 0.81 |
| Accrued Expenses | 12.75 | 14.37 | 14.66 | 4.32 | 2.84 | 0.43 |
| Current Portion of Leases | 0.39 | - | 0.34 | 0.32 | 0.16 | 0.11 |
| Other Current Liabilities | 0.09 | 0.2 | 10.36 | 1.64 | 0.23 | 0.14 |
| Total Current Liabilities | 14.65 | 15.92 | 25.89 | 9.72 | 5.75 | 1.48 |
| Long-Term Leases | 0.1 | - | - | 0.28 | - | - |
| Other Long-Term Liabilities | - | - | 0.07 | 0.38 | 0.71 | 0.08 |
| Common Stock | 0.06 | 0.05 | 0.04 | 0 | 0 | 0 |
| Additional Paid-In Capital | 793.34 | 553.21 | 400.17 | 6.04 | 2.31 | 0.16 |
| Retained Earnings | -317.5 | -243.47 | -154.45 | -82.86 | -45.2 | -20.46 |
| Comprehensive Income & Other | 0.22 | 0.06 | 0.14 | - | - | - |
| Total Common Equity | 476.12 | 309.85 | 245.91 | -76.83 | -42.89 | -20.3 |
| Total Liabilities & Equity | 490.88 | 325.76 | 271.87 | 83.3 | 113.33 | 131 |
| Total Debt | 0.49 | - | 0.34 | 0.6 | 0.16 | 0.11 |
| Net Cash (Debt) | 477.08 | 313.44 | 252.81 | 74.94 | 109.87 | 130.26 |
| Net Cash Growth | 63.52% | 23.98% | 237.37% | -31.79% | -15.66% | - |
| Net Cash Per Share | 8.91 | 6.66 | 7.11 | 23.99 | 14.06 | 26.12 |
| Filing Date Shares Outstanding | 59.35 | 49 | 41.35 | 12.1 | 11.64 | 4.99 |
| Total Common Shares Outstanding | 59.26 | 48.94 | 41.29 | 12.1 | 11.64 | 4.99 |
| Working Capital | 468.03 | 302.21 | 240.26 | 68.04 | 104.92 | 129.11 |
| Book Value Per Share | 8.03 | 6.33 | 5.96 | -6.35 | -3.68 | -4.07 |
| Tangible Book Value | 476.12 | 309.85 | 245.91 | -76.83 | -42.89 | -20.3 |
| Tangible Book Value Per Share | 8.03 | 6.33 | 5.96 | -6.35 | -3.68 | -4.07 |
| Machinery | 1.54 | 1.38 | 1.41 | 1.26 | 0.65 | 0.46 |
Source: S&P Capital IQ. Standard template.
Financial Sources.